Microangiopathic Hemolytic Anemia

Article written and reviewed by Dr Luca Moretti

Microangiopathic hemolytic anemia (MAHA, Microangiopathic Hemolytic Anemia) is a clinical and hematologic syndrome characterized by mechanical destruction of red blood cells within the microcirculation, resulting in hemolytic anemia and the presence of schistocytes on the peripheral blood smear. Unlike autoimmune hemolytic anemias or membrane disorders, MAHA is not a single disease, but a pathogenetic mechanism shared by several systemic syndromes that are often severe and potentially fatal.

This phenomenon occurs mainly in conditions such as thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), HELLP syndrome and preeclampsia, but it may also occur in autoimmune, neoplastic and infectious diseases and as a complication of medications or transplantation. In all these settings, the common denominator is endothelial injury and the formation of microvascular thrombi, which impair blood flow through small vessels and cause erythrocyte injury and fragmentation.

Microangiopathic hemolytic anemia is therefore a true hematologic emergency. Prompt diagnosis and correct identification of the underlying disorder are decisive for prognosis and survival. Management requires a multidisciplinary approach integrating clinical recognition, laboratory investigations and therapeutic strategies directed at the primary cause.

Etiology

Microangiopathic hemolytic anemia develops as a direct consequence of pathologic processes that injure the microcirculation and produce thrombi within small vessels, followed by mechanical destruction of erythrocytes. The microvascular mechanism varies with the etiology and may involve endothelial injury, platelet aggregation, complement activation or coagulation activation, resulting in impaired blood flow and erythrocyte fragmentation.

The main direct causes of MAHA include:

• Thrombotic thrombocytopenic purpura (TTP): caused by congenital or acquired deficiency of the ADAMTS13 protease, with accumulation of von Willebrand factor multimers and formation of platelet thrombi.
• Hemolytic uremic syndrome (HUS): classically induced by intestinal infection with Escherichia coli producing Shiga toxin, or by genetic or acquired complement dysregulation (complement mediated HUS).
• Disseminated intravascular coagulation (DIC): resulting from systemic activation of the coagulation cascade due to sepsis, malignancy, trauma or obstetric disorders.
• HELLP syndrome and preeclampsia: pregnancy related conditions associated with diffuse endothelial injury and microthrombosis.
• Other primary causes: systemic vasculitis, malignant hypertensive crises, medication reactions involving mitomycin C, cyclosporine or ticlopidine, post transplant complications, severe infections and metastatic malignancies.

In all these conditions, endothelial injury and deposition of microvascular thrombi initiate the hemolytic process typical of MAHA.

Risk factors and prevention

Although MAHA is caused by direct and well defined mechanisms, certain factors may increase the probability of developing this syndrome in the presence of an underlying predisposing disorder. The main risk factors are:

• Pregnancy, especially during the third trimester because of the risk of HELLP syndrome and preeclampsia
• Immunosuppressive or chemotherapeutic treatments, particularly with medications known to have endothelial toxicity
• Solid organ or bone marrow transplantation, with a risk of post transplant microangiopathic complications
• Severe infections, whether bacterial, viral or fungal, in immunocompromised patients
• Systemic autoimmune diseases, including lupus and antiphospholipid syndrome
• Advanced malignancies or metastatic disease
• Severe endothelial or vascular injury, such as malignant hypertension

Prevention of MAHA is closely linked to prompt control and management of underlying disorders, early identification of patients at risk and limitation of exposure to medications that may damage the endothelium.

Pathogenesis and pathophysiology

The pathogenesis of microangiopathic hemolytic anemia depends on the cause and involves alteration of the microcirculation with microthrombi or vascular injury whose composition and mechanism vary; in TTP, platelet and von Willebrand factor rich microthrombi predominate, with little fibrin. These thrombi obstruct normal blood flow through small vessels and create a mechanically unfavorable environment for erythrocytes.

As red blood cells pass through these altered vascular segments, they are exposed to abnormal shear forces and fragment, producing the characteristic schistocytes. This process causes intravascular hemolysis with increased LDH, reduced haptoglobin and increased indirect bilirubin. The resulting anemia is frequently, but not invariably, accompanied by consumptive thrombocytopenia.

The pathophysiologic process can be summarized as follows:

• Microvascular injury or occlusion through a mechanism that varies according to the etiology
• Formation of microthrombi whose composition varies according to the etiology
• Mechanical fragmentation of erythrocytes with production of schistocytes
• Acute hemolytic anemia and consumptive thrombocytopenia
• Ischemia and multiorgan dysfunction due to impaired microcirculation

In the most severe cases, the microangiopathic process may rapidly progress to acute kidney failure, neurologic involvement, liver injury and multiorgan dysfunction syndrome, making prognosis closely dependent on the speed of diagnosis and treatment of the causative disorder.

Clinical presentation

The clinical presentation of microangiopathic hemolytic anemia is extremely variable and reflects both the severity of hemolysis and the systemic involvement caused by the underlying disorder. Symptoms develop acutely or subacutely and are often accompanied by signs of multiorgan failure, making MAHA a true medical emergency.

The cardinal finding is the onset of acute anemia, often rapidly progressive, associated with pallor, marked fatigue, tachycardia and dyspnea. A variable degree of thrombocytopenia is also present and may manifest with petechiae, ecchymoses and a bleeding tendency. Mild jaundice due to increased indirect bilirubin is not uncommon, whereas hemoglobinuria may be detected in the most severe forms of intravascular hemolysis.

Additional clinical manifestations depend on the underlying microangiopathic disorder and the extent of organ injury:

• Neurologic symptoms: confusion, headache, focal deficits, seizures and coma, which are typical of thrombotic thrombocytopenic purpura
• Signs of acute kidney failure: oliguria or anuria, increased creatinine and generalized edema, which are more pronounced in hemolytic uremic syndrome
• Gastrointestinal symptoms: abdominal pain, nausea, vomiting and diarrhea, which are frequent in HUS and DIC
• Signs of liver dysfunction: elevated transaminases, coagulopathy and hyperbilirubinemia
• Respiratory impairment: progressive dyspnea and acute respiratory failure in severe DIC or HELLP syndrome

Overall, the natural history of MAHA is strongly influenced by progression of the underlying disease. Recovery may be complete when treatment is initiated early, whereas otherwise multiorgan failure may rapidly lead to death.

Several characteristic clinical syndromes can be recognized in typical presentations:

• Thrombotic thrombocytopenic purpura: the classic pentad comprises microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, fever and kidney injury, but it is present in only a minority of patients and should not be awaited before raising suspicion or starting the urgent treatment pathway.
• Hemolytic uremic syndrome: the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney failure, more common in children.
• HELLP syndrome: hemolysis, elevated transaminases and thrombocytopenia during pregnancy, often associated with preeclampsia.
• DIC: a hemorrhagic and thrombotic syndrome with systemic and organ specific manifestations.

Prompt recognition of these syndromic presentations is essential to initiate the most appropriate diagnostic and therapeutic pathway without delay.

Investigations and Diagnosis

The diagnosis of microangiopathic hemolytic anemia is based on an integrated approach combining clinical findings with laboratory and instrumental confirmation. Suspicion arises when hemolytic anemia is associated with thrombocytopenia and signs of organ involvement, especially in patients with known systemic disease or risk factors.

Initial diagnostic workup:

• Complete blood count: generally normocytic, normochromic anemia with variable reticulocytosis and often marked thrombocytopenia.
• Peripheral blood smear: the key investigation, showing schistocytes, or erythrocyte fragments, poikilocytosis, polychromasia and occasionally circulating erythroblasts.
• Hemolysis markers: increased LDH, increased indirect bilirubin, reduced haptoglobin, increased plasma free hemoglobin and a negative direct antiglobulin test.
• Urinalysis: possible hemoglobinuria, proteinuria and casts in cases with acute kidney injury.

Identification of schistocytes above 1% on the peripheral blood smear is strongly suggestive of thrombotic microangiopathy, but is not specific in isolation and must be interpreted within the clinical and laboratory context.

Second line investigations: Targeted investigations are selected according to the suspected etiology:

• ADAMTS13 activity measurement: for the diagnosis of TTP, with severe deficiency below 10% being highly suggestive. The sample should be collected before plasma exchange whenever possible, but when clinical suspicion is high, treatment must not be delayed while awaiting the result.
• Pretest probability of TTP: while awaiting ADAMTS13 results, suspicion should be quantified by integrating the clinical picture with a validated score such as the PLASMIC score or French score, without delaying treatment in patients with high probability.
• Testing for STEC or Shiga toxin: in compatible acute diarrheal illnesses and suspected STEC associated HUS, even in the absence of visible blood in the stool
• Coagulation studies: PT, aPTT, fibrinogen and D dimer for the diagnosis of DIC
• Autoimmune testing: ANA, antiphospholipid antibodies and C3/C4 according to the clinical suspicion
• Assessment of kidney and liver function and markers of organ injury
• Renal and liver ultrasonography in the presence of organ failure

These investigations define the syndromic picture, guide the differential diagnosis and exclude other forms of hemolytic anemia, including autoimmune, membrane and enzymatic disorders.

Differential diagnosis: The differential diagnosis includes other causes of hemolytic anemia, with a generally positive direct antiglobulin test in autoimmune forms, although rare DAT negative AIHA exists; enzyme deficiencies and hemoglobinopathies should also be considered. Other considerations include thrombocytopenia of other causes, nonhemolytic microangiopathies and acute multisystem disorders such as sepsis, acute liver or kidney failure and transfusion reactions.

Specialist consultation: In severe cases, prompt involvement of a hematologist, nephrologist, intensivist or obstetrician is essential for multidisciplinary management and initiation of specific treatment.

Early diagnosis of MAHA and rapid identification of the underlying cause are prerequisites for effective treatment that can reduce mortality and prevent permanent sequelae.

Treatment and Prognosis

The treatment of microangiopathic hemolytic anemia is based on an individualized strategy directed first at removing or controlling the underlying cause and rapidly interrupting the hemolytic and thrombotic process. The primary goals are to prevent multiorgan failure, correct acute anemia and thrombocytopenia, limit organ injury and improve survival. In many cases, MAHA is an urgent medical condition or emergency requiring prompt, multidisciplinary and often complex intervention.

Management of the primary cause:

• Immune thrombotic thrombocytopenic purpura (TTP): acute treatment requires urgent plasma exchange and corticosteroids; caplacizumab is added early in appropriate patients according to the clinical and diagnostic context. Rituximab is commonly used early to reduce autoantibodies and relapses. Cyclophosphamide is reserved for exceptional refractory rescue settings.
• Congenital thrombotic thrombocytopenic purpura (cTTP): during remission, ADAMTS13 replacement is indicated; according to the 2025 ISTH update, recombinant ADAMTS13 is preferred to plasma when available, whereas if it is unavailable, fresh frozen plasma is preferable to observation alone.
• Hemolytic uremic syndrome (HUS): intensive supportive care is fundamental in Shiga toxin associated forms; in complement mediated forms, complement inhibition with eculizumab or other authorized medications is an effective targeted therapy according to the indication.
• Disseminated intravascular coagulation (DIC): therapy is directed at treating the precipitating cause, such as infection, malignancy or trauma, with hemostatic support using plasma, platelets and coagulation factors and attention to hemorrhagic and thrombotic complications.
• HELLP syndrome and preeclampsia: maternal stabilization and delivery are the priorities; intensive management is necessary in severe cases to prevent progression to multiorgan failure.
• Other forms: discontinuation of toxic medications, treatment of malignancies or infections and correction of metabolic complications are cornerstones of therapy.

Treatment of the underlying disorder must always be accompanied by rigorous clinical and laboratory surveillance to promptly identify any deterioration or acute complications.

Supportive therapies:

• Packed red blood cell transfusions for severe symptomatic anemia, while avoiding volume overload in patients with kidney or heart failure.
• Platelet transfusions: in thrombotic microangiopathies, especially TTP, they are routinely avoided and generally reserved for clinically significant bleeding or urgent procedures; in DIC and other settings, the indication depends on the count, bleeding and planned procedure.
• Ventilatory, dialysis, nutritional and pharmacologic support as required and according to multiorgan dysfunction.

Management should always be entrusted to specialist centers, with intensive monitoring of hematologic, biochemical and organ function parameters.

Prognosis: The prognosis of MAHA depends closely on the speed of diagnosis and effectiveness of causal treatment. In forms treated early, recovery may be complete; delays in identification or therapy may rapidly lead to multiorgan failure, permanent disability or death. In particular, mortality from untreated TTP exceeds 90%, whereas plasma exchange and modern therapies have radically improved long term survival. In the other forms as well, prognosis is linked to control of complications and prevention of recurrence.

Hematologic and internal medicine follow up is essential for survivors to monitor late sequelae, including chronic kidney disease, neurologic dysfunction and coagulation abnormalities.

The prevention of MAHA primarily involves appropriate management of risk factors, including high risk pregnancy, use of medications with high endothelial toxicity potential, prevention of infections and surveillance of immunocompromised patients, together with prompt recognition of predisposing conditions and close collaboration among specialists.

Complications

The complications of microangiopathic hemolytic anemia are the main cause of morbidity and mortality, especially in acute or untreated forms. The risk of complications is proportional to the severity of the microangiopathy, speed of progression and presence of predisposing factors or concomitant disorders. Accumulating microvascular injury and multiorgan dysfunction require careful surveillance and intensive management.

Organ complications:

• Acute kidney failure: particularly common in HUS and DIC and may progress to chronic kidney disease.
• Neurologic injury: encephalopathy, seizures, ischemic or hemorrhagic stroke and persistent cognitive deficits, characteristic of TTP and severe forms of DIC.
• Liver injury: marked elevation of transaminases, coagulopathy and hepatic necrosis, especially in HELLP syndrome and DIC.
• Acute or chronic heart failure: due to microvascular ischemia or severe anemia.
• Pulmonary dysfunction: noncardiogenic pulmonary edema and acute respiratory failure.

Hematologic and thrombotic complications:

• Severe hemorrhage, including cerebral, gastrointestinal and pulmonary bleeding, secondary to thrombocytopenia and coagulopathy
• Venous and arterial thrombosis due to coagulation hyperactivation
• Recurrence of microangiopathy, especially if the causal trigger is not removed

Infectious complications: Infections may be part of the initial cause or complicate the course in critically ill patients, especially in the presence of invasive devices, organ failure or immunosuppressive therapies. Transfusions themselves do not cause immunosuppression.

Late complications and sequelae: Survivors of severe MAHA episodes may have persistent neurologic injury, chronic kidney disease, cognitive deficits or post intensive care syndrome, which substantially affect quality of life and life expectancy.

Overall, management of complications in MAHA requires multidisciplinary monitoring, early care and targeted rehabilitation, with the aim of reducing long term disability and mortality.

Bibliography
1. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666.
2. Scully M, Cataland SR, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–322.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589–600.
4. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3):831–846.
5. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153–E159.
6. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006;70(1):16–23.
7. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60–68.
8. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998;9(6):1126–1133.
9. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846.
10. Nguyen TC, Carcillo JA. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure—a newly appreciated syndrome in the critically ill. Crit Care. 2006;10(6):235.
11. Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2015;2015(1):631–636.
12. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15–23.
13. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393–397.
14. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3(8):1663–1675.
15. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335–346. doi:10.1056/NEJMoa1806311.
16. Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23(11):3711–3732. doi:10.1016/j.jtha.2025.06.002.